Faculty of General Medicine, Yerevan State Medical University After Mkhitar Heratsi, Yerevan, Armenia.
Department of Surgery, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Microb Pathog. 2022 Nov;172:105514. doi: 10.1016/j.micpath.2022.105514. Epub 2022 May 7.
Vibrio cholera (V. cholera) is a facultative pathogen that colonizes the small intestine and produces cholerae toxin as the primary virulence factor that causes cholera and fatal diarrhea in humans. In recent decades, V. cholera has emerged as a notorious multidrug-resistant enteric pathogen. This meta-analysis estimated the pooled proportion of V. cholera antimicrobial resistance against RNA and DNA effective antibiotics.
A systematic search was performed for relevant literature until 05 June 2021 in PubMed, Scopus, Embase, and Web of Science databases. Freeman-Tukey double arcsine transformation was performed to estimate weighted pooled resistance (WPR).
The meta-analysis were included 164 articles. The WPR of V. cholera were as follows 76% [67,84] to furazolidone, 65% [29,94] to nitrofurantoin, 55% [44,66] to nalidixic acid, 10% [2,23] to rifampicin, 4%(0, 12) to novobiocin, 4% [2,6] to norfloxacin, 3% [1,4] to ciprofloxacin, 1%(0, 3) to sparofloxacin, 0%(0, 3) to levofloxacin, 0%(0, 2) to ofloxacin, 0%(0, 0) to gatifloxacin.
V. cholera is a severe problem in Asia and Africa, especially in South Asian countries. The resistance patterns are various in geographical regions. novobiocin 0% (0, 0), and ofloxacin 0% (0, 1) in Africa, gatifloxacin 0% (0, 0), and levofloxacin 0% (0, 6) in Asia and ciprofloxacin 0% (0, 2) in North America are most effective antibiotis. The resistance rate to furazolidone, nalidixic acid, nitrofurantoin, and cephalothin has increased over the years. Monitoring antibiotic resistance and prescribing an appropriate antibiotic is vital to control resistance.
霍乱弧菌（V. cholera）是一种兼性病原体，它定殖于小肠并产生霍乱毒素作为主要的毒力因子，导致人类霍乱和致命性腹泻。近几十年来，霍乱弧菌已成为一种臭名昭著的多药耐药肠道病原体。本荟萃分析估计了霍乱弧菌对 RNA 和 DNA 有效抗生素的抗菌药物耐药率的合并比例。
在 PubMed、Scopus、Embase 和 Web of Science 数据库中进行了系统性检索，检索截至 2021 年 6 月 05 日的相关文献。采用 Freeman-Tukey 双反正弦变换来估计加权合并耐药率（WPR）。
荟萃分析纳入了 164 篇文章。V. cholera 的 WPR 如下：呋喃唑酮耐药率为 76% [67,84]，呋喃妥因耐药率为 65% [29,94]，萘啶酸耐药率为 55% [44,66]，利福平耐药率为 10% [2,23]，新生霉素耐药率为 4%（0, 12），诺氟沙星耐药率为 4% [2,6]，环丙沙星耐药率为 3% [1,4]，司帕沙星耐药率为 1%（0, 3），左氧氟沙星耐药率为 0%（0, 3），氧氟沙星耐药率为 0%（0, 2），加替沙星耐药率为 0%（0, 0）。
霍乱弧菌在亚洲和非洲，特别是南亚国家，是一个严重的问题。地理区域的耐药模式各不相同。在非洲，新生霉素耐药率为 0%（0, 0），氧氟沙星耐药率为 0%（0, 1）；在亚洲，加替沙星耐药率为 0%（0, 0），左氧氟沙星耐药率为 0%（0, 6）；在北美，环丙沙星耐药率为 0%（0, 2）是最有效的抗生素。呋喃唑酮、萘啶酸、呋喃妥因和头孢噻肟的耐药率近年来有所上升。监测抗生素耐药性并开具适当的抗生素对控制耐药性至关重要。
